

**This document is a Supplement to the Prospectus dated 26 March 2025 issued by Global X ETFs ICAV (the “ICAV”). This Supplement forms part of, and should be read in conjunction with, the Prospectus.**

Investors’ attention is drawn to the risk warnings contained in the section of the Prospectus entitled “Risk Factors” and, in particular, to the risk warnings contained in the section of this Supplement entitled “Risk Factors”.

Words and expressions defined in the Prospectus, unless the context otherwise requires, have the same meaning when used in this Supplement.

## **SUPPLEMENT**

**in respect of**

### **GLOBAL X GENOMICS & BIOTECHNOLOGY UCITS ETF (the “Fund”)**

#### **a UCITS ETF Sub-Fund of the Global X ETFs ICAV**

an open-ended Irish collective asset-management vehicle having registration number C435449 and established as an umbrella fund with segregated liability between sub-funds and authorised by the Central Bank of Ireland as a UCITS.

**Dated 9 May 2025**

The Directors of the ICAV, whose names appear in the Directory in the Prospectus, accept responsibility for the information contained in this Supplement. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

## THE FUND

---

### Investment Objective

The investment objective of the Fund is to provide investment results that closely correspond, before fees and expenses, generally to the price and yield performance of the Solactive Genomics v2 Index (the “Index”).

### Investment Policy

In order to achieve this investment objective, the Fund will seek to replicate the performance of the Index, subject to the deduction of the TER and other expenses associated with operating the Fund as further described in the “Fees and Expenses” section of the Prospectus. It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and in American Depositary Receipts (“ADRs”) and Global Depositary Receipts (“GDRs”) based on the securities in the Index. **By holding each equity security in approximately the same proportion as its weighting in the Index, the Fund may have exposure to or invest up to 20% of the Net Asset Value of the Fund in stocks issued by the same body.**

The Fund is not classified as an Article 8 or Article 9 fund pursuant to SFDR, however, disclosure in accordance with the requirements of Article 6 of SFDR in relation to the integration of sustainability risks is set out in the Prospectus.

The Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, “**Genomics & Biotechnology Companies**”), as defined by Solactive AG (the “**Index Provider**”). In order to be eligible for inclusion in the Index, a company is considered by the Index Provider to be included if it generates revenues from relevant activities:

1. Pure-Play which derives at least 50% of revenues from genomics activities which means a process that involves exploring and understanding the structure, function, and evolution of genomes (“**Genomics Activities**”).
2. Pre-Revenue which has primary business operations in Genomics Activities but does not currently generate revenues.
3. Diversified which derives revenues from Genomics Activities but less than 50%.

In constructing the Index, the Index Provider first establishes the eligible universe by utilising FactSet sector classifications. FactSet is a financial data and software company that provides integrated data and software services for a variety of different industries. Only companies classified by FactSet as healthcare companies are eligible for the Index. The Index Provider then applies a proprietary natural language processing algorithm to the eligible universe, which seeks to identify and rank companies with direct exposure to the genomics industry based on filings, disclosures and other public information (e.g. regulatory filings, earnings transcripts, etc.). Genomics business operations include but are not limited to the following:

- i. Gene Editing: Companies that develop technology for the insertion, deletion, or replacement of DNA at a specific site in the genome of an organism.
- ii. Genomic Sequencing: Companies that are engaged in the process of determining the complete DNA sequence of an organism's genome.
- iii. Development and Testing Genetic Medicine/Therapies: Companies that seek to detect, cure or treat diseases by identifying and/or modifying an organism's gene expression or functioning.
- iv. Computational Genomics and Genetic Diagnostics: Companies that use computational and statistical analysis to decipher biological insights from genome sequences and related data.

The remaining companies are ranked by their Index Score. If there are two or more companies that share the last rank, then preference is given to the company with the highest market capitalisation :

1. The 20 highest ranking Pure-Play/Pre-Revenue companies are added as final Index constituents.
2. The 5 highest diversified companies are added as final index constituents.
3. Current index constituents that fulfil the following requirements are added as Index constituents by priority of their weight as of the selection day until there are a maximum of 50 Index constituents:
  - i) The Index constituent has an index score.
  - ii) The Genomics Activities constituent satisfies the Index component requirements.
  - iii) If the total number of Index constituents is still below 50 after the previous steps, companies that satisfy the index universe requirements are added as Index constituents according to their Index Score, until there are a maximum of 50 Index constituents. Diversified Index constituents will be capped at 10 Index constituents.

(together the "**Index Score**").

The eligible universe of the Index includes exchange-listed companies that meet minimum market capitalisation and liquidity criteria, as defined by the Index Provider. As of 15 May 2023, companies must have a minimum market capitalisation of \$200 million and a minimum average daily turnover for the last 6 months greater than or equal to \$2 million in order to be eligible for inclusion in the Index. As of 13 December 2024, companies listed in the following countries were eligible for inclusion in the Index: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, the United Kingdom, and the United States.

The Investment Manager uses a "passive" or indexing approach to try to achieve the Fund's investment objective. The Fund does not try to "outperform" the Index and does not seek temporary defensive positions when markets decline or appear overvalued.

Where it is not possible or practicable for the Fund to invest directly in or continue to hold all of the component securities of the Index (for reasons such as, but not limited to, where this would involve difficulties or substantial costs, where one or more securities in the Index becomes temporarily illiquid or unavailable, or as a result of legal restrictions or regulatory limitations that apply to the Fund but not the Index) and/or where consistent with its investment objective, the Fund may also invest in the following additional assets subject to the conditions and within the limits laid down by the Central Bank:

- Depositary Receipts relating either to component securities of the Index or to equity securities of the type referred to above;

- FDIs – namely, total return “unfunded” OTC Swaps and exchange-traded equity futures – which may be used for investment purposes (such as gaining exposure to the Index and/or any particular constituents of the Index) in accordance with the terms set out in the sections entitled “Fund Investments”, “Unfunded OTC Swap Model” and Schedule II of the Prospectus. While the Fund may invest up to 100% of its Net Asset Value in total return “unfunded” OTC Swaps, it is not expected that this flexibility will be used. The Fund will only invest in FDIs as provided for in the RMP prepared by the Investment Manager in respect of the Fund and filed with the Central Bank;
- Equity securities which are not constituents of the Index, which, in the opinion of the Investment Manager, are expected to provide similar performance and risk characteristics to the Index constituent(s) which are not possible or practicable for the Fund to invest directly in or continue to hold; and
- Collective investments schemes that have a similar strategy to the Fund or allow similar exposure to the Index constituents.

The equity securities and FDI investments of the Fund will be listed, traded and dealt with on one or more of the Regulated Markets set out in Schedule 1 to the Prospectus.

The Fund may, in addition, employ other techniques relating to transferable securities, including entering into securities lending transactions, investing in repurchase and reverse repurchase transactions and collective investment schemes, for the purpose of efficient portfolio management only, in accordance with the terms set out in the section entitled “**Efficient Portfolio Management Techniques**” and Schedule III of the Prospectus. While the Fund may invest up to 100% of its Net Asset Value in repurchase and reverse repurchase transactions it is not expected that this flexibility will be used.

The maximum proportion of the Net Asset Value of the Fund that can be subject to securities lending is 50%. The proportion of the Net Asset Value of the Fund that will be subject to securities lending is expected to range from 0% to 50%.

The maximum proportion of the Net Asset Value of the Fund that can be subject to repurchase transactions is 20%. The proportion of the Net Asset Value of the Fund that will be subject to repurchase transactions is expected to be 0%.

The maximum proportion of the Net Asset Value of the Fund that can be subject to reverse repurchase transactions is 20%. The proportion of the Net Asset Value of the Fund that will be subject to reverse repurchase transactions is expected to be 0%.

The maximum proportion of the Net Asset Value of the Fund that can be subject to total return swaps is 20%. The proportion of the Net Asset Value of the Fund that will be subject to total return swaps is expected to be 0%.

As at the date of this Fund Supplement, to the extent the Fund undertakes securities lending, the Fund will receive 87% of the associated revenue generated from securities lending activities and the remaining 13% will be retained by the securities lending agent (representing the attendant direct and indirect operational

costs and fees of the securities lending). In circumstances where the attendant direct and indirect operational costs and fees of the securities lending are less than 13% of the revenue generated from securities lending activities, the excess revenue will be returned to the Fund.

### **Base Currency**

The Base Currency of the Fund is USD.

### **Investment Manager**

The Investment Manager of the Fund is Global X Management Company LLC.

**There is no guarantee that the Fund will achieve its investment objective.**

**It is recommended that an investment in the Fund should not constitute a substantial proportion of an investment portfolio and may not be appropriate for all investors.**

### **PROFILE OF A TYPICAL INVESTOR**

---

A typical investor in the Fund would want to take a long or short-term exposure to the market covered by the Index and would be prepared to accept the medium level risks associated with an investment of this type, including the potential volatility of such market. Such an investor is also one that is able to assess the merits and risks of an investment in the Shares of the relevant Class of the Fund.

### **SHARE CLASSES**

---

Only ETF Shares will be issued in respect of the Fund.

Details of the Classes available in the Fund, are set out below.

<b>Classes</b>	<b>TER</b>	<b>Dividend Policy/Frequency</b>	<b>Unlaunched Classes of ETF Shares are indicated below</b>	<b>Hedged share Class</b>	<b>Class Currency</b>
USD Accumulating	0.50%	Accumulating	Unlaunched	No	USD
EUR Accumulating	0.50%	Accumulating	Unlaunched	No	EUR
GBP Accumulating	0.50%	Accumulating	Unlaunched	No	GBP
CHF Accumulating	0.50%	Accumulating	Unlaunched	No	CHF
USD Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	No	USD
EUR Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	No	EUR
GBP Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	No	GBP
CHF Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	No	CHF
USD Hedged Accumulating	0.50%	Accumulating	Unlaunched	Yes	USD
EUR Hedged Accumulating	0.50%	Accumulating	Unlaunched	Yes	EUR
GBP Hedged Accumulating	0.50%	Accumulating	Unlaunched	Yes	GBP
CHF Hedged Accumulating	0.50%	Accumulating	Unlaunched	Yes	CHF
USD Hedged Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	Yes	USD
EUR Hedged Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	Yes	EUR
GBP Hedged Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	Yes	GBP
CHF Hedged Distributing	0.50%	Distributing (Semi-annually)	Unlaunched	Yes	CHF

The Directors reserve the right to differentiate between persons who are subscribing for or redeeming Shares and to waive or reduce the Minimum Subscription Amount and Minimum Redemption Amount for any such person or to refuse an application for the subscription of Shares in their absolute discretion.

Additional Classes may be created in accordance with the requirements of the Central Bank.

## TRACKING ERROR

---

The anticipated tracking error in normal market conditions is set out below for each of the Classes of the Fund. Please note that, whilst the Fund has multiple Classes some of which are denominated in different currencies, some of which are distributing Classes and/or some of which are Hedged Classes, the anticipated tracking error displayed for all Classes is that applicable for the USD Accumulating (which is denominated in USD, unhedged and accumulates any applicable dividends) as against the Index (which is also denominated in USD, unhedged and accumulates any applicable dividends).

The anticipated tracking error of a Class is not a guide to its future performance. The annual and semi-annual report and accounts will set out the actual realised tracking error as at the end of the period under review.

<b>Classes</b>	<b>Tracking Error</b>
USD Accumulating	1% (annualised)
EUR Accumulating	1% (annualised)
GBP Accumulating	1% (annualised)
CHF Accumulating	1% (annualised)
USD Distributing	1% (annualised)
EUR Distributing	1% (annualised)
GBP Distributing	1% (annualised)
CHF Distributing	1% (annualised)
USD Hedged Accumulating	1% (annualised)
EUR Hedged Accumulating	1% (annualised)
GBP Hedged Accumulating	1% (annualised)
CHF Hedged Accumulating	1% (annualised)
USD Hedged Distributing	1% (annualised)
EUR Hedged Distributing	1% (annualised)
GBP Hedged Distributing	1% (annualised)
CHF Hedged Distributing	1% (annualised)

## DIVIDENDS

---

Where the ICAV intends to declare dividends with respect to one or more Classes of the Fund, the proposed frequency of such dividend declarations shall be as set out in the table in the section entitled “*Share Classes*”.

It is not the current intention of the Directors to declare dividends in respect of the Classes identified as “accumulating” classes in this Supplement. The income and earnings and gains of the Funds will be accumulated and reinvested. Any change to this dividend policy shall be set out in an updated version of the Supplement and notified to the Shareholders in advance.

It is intended to declare dividends in respect of the Classes identified as “distributing” classes in this Supplement. Distributions in respect of these Classes will be declared on each Distribution Date in each

year provided that if such dates are not Business Days, the declaration date will be the Business Day immediately following such date respectively. The distribution may comprise net income (if any) of the Fund.

The Distribution Date for this Fund will be as noted on the distribution calendar available at <https://globalxetfs.eu>.

### Payments

With the authorisation and upon the instruction of the Common Depositary's Nominee, any dividends declared and any liquidation and mandatory redemption proceeds are paid by the ICAV or its authorised agent (for example, a paying agent) to the applicable ICSD. Investors, where they are Participants, must look solely to the applicable ICSD for their share of each dividend payment or any liquidation or mandatory redemption proceeds paid by the ICAV or, where they are not Participants, they must look to their respective nominee, broker or Central Securities Depositary (as appropriate, which may be a Participant or have an arrangement with a Participant of the applicable ICSD) for any share of each dividend payment or any liquidation or mandatory redemption proceeds paid by the ICAV that relates to their investment.

Investors shall have no claim directly against the ICAV in respect of dividend payments and any liquidation and mandatory redemption proceeds due on Shares represented by the Global Share Certificate and the obligations of the ICAV will be discharged by payment to the applicable ICSD with the authorisation of the Common Depositary's Nominee.

## **DEALING IN SHARES OF THE FUND**

---

Only the ETF Shares issued in respect of this Fund will be listed and/or traded on the Relevant Stock Exchanges. It is envisaged that ETF Shares will be bought and sold by private and institutional investors in the secondary market.

Only Authorised Participants may subscribe for and redeem ETF Shares in the Fund directly with the ICAV in accordance with the section of the Prospectus entitled “**Subscriptions and Redemptions**” having regard to the information set out below:

<b>Business Day</b>	A day on which the New York Stock Exchange and London Stock Exchange is open for normal business.
<b>Class Currency</b>	The dealing currency and the currency of denomination of the relevant Class.
<b>Dealing Day</b>	On each Business Day.
<b>Initial Offer Period</b>	The Initial Offer Period shall only apply to unlaunched Classes and shall commence at 9 a.m. (Dublin time) on 12 May 2025 and shall end at 3 p.m. (Dublin time) on 12 November 2025 or such other time as the Directors may determine.



<b>Initial Offer Price</b>	The price per Share is expected to be approximately USD 15, or its equivalent in the Class Currency. However, the actual initial price per ETF Share will depend on the actual cost to the ICAV of purchasing the relevant Investments (please see the definition of “ <b>Duties and Charges</b> ” in the Prospectus). Details of the Initial Offer Price will be available from the Administrator and on <a href="https://globalxetfs.eu">https://globalxetfs.eu</a>
<b>Minimum Redemption Amount</b>	1 Creation Unit of 10,000 Shares or its cash equivalent
<b>Minimum Subscription Amount</b>	1 Creation Unit of 10,000 Shares or its cash equivalent
<b>Settlement Time</b>	<p>Settlement of subscriptions shall generally occur within one Business Day after the relevant Dealing Day (unless otherwise stipulated by the Manager or its delegate) and in any event will occur within a maximum of ten Business Days.</p> <p>Settlement of redemptions shall generally occur within two Business Days after the relevant Dealing Day (unless otherwise agreed with the Manager or its delegate).</p>
<b>Subscription Fee</b>	None
<b>Redemption Fee</b>	None
<b>Trade Cut-Off Time</b>	<p>4:30 p.m. (London time) on the Business Day prior to the relevant Dealing Day or such earlier or later time as may be determined by the Manager or the Investment Manager at their discretion with prior notice to Authorised Participants, which is the cut-off time in respect of any Dealing Day for receipt of applications for subscriptions and redemptions in the Fund.</p> <p>The Trade Cut-Off Time for this Fund reflects that some, or all, of the Fund's underlying assets are traded in time zones earlier than the European time zone.</p>
<b>Valuation Point</b>	4:00 p.m. New York time on the relevant Dealing Day.

## **FEES AND EXPENSES**

---

A TER will be paid out of the assets of each Class to the ICAV. The TER for each Class is set out under the heading “TER” in the table included under the heading “**Share Classes**”.

This section should be read in conjunction with the section headed “**Fees, Costs and Expenses**” in the Prospectus.

## RISK FACTORS

---

Investment in the Fund carries with it a degree of risk including, but not limited to, the risks described in the “**Risk Factors**” section of the Prospectus including particularly Securities Lending Risk, Concentration Risk, Non-Diversification Risk, Risk of Investing in Developed Markets, New Fund Risk and the following:

Given the investment strategy of the Fund and its risk profile, the likely impact of sustainability risks on the Fund’s returns is expected to be low.

**Associated Risks Related to Investing in Genomics Companies:** Genomics companies typically face intense competition and potentially rapid product obsolescence. These companies are also heavily dependent on intellectual property rights and may be adversely affected by loss or impairment of those rights. There can be no assurance these companies will be able to successfully protect their intellectual property to prevent the misappropriation of their technology, or that competitors will not develop technology that is substantially similar or superior to such companies’ technology. Genomics companies typically engage in significant amounts of spending on research and development, and there is no guarantee that the products or services produced by these companies will be successful. In addition, the field of genomic science could face increasing regulatory scrutiny in the future, which may limit the development of this technology and impede the growth of companies that develop and/or utilise this technology. The customers and/or suppliers of genomics companies may be concentrated in a particular country, region or industry. Any adverse event affecting one of these countries, regions or industries could have a negative impact on genomics companies. Through its portfolio companies’ customers and suppliers, the Fund is specifically exposed to **Asian Economic Risk**, **North American Economic Risk** and **European Economic Risk**. Demand for Genomics products, generally speaking and specific to sub-segments, may fluctuate due to unexpected events, including but not limited to global health crises like pandemics which could strain health care systems and alter health care needs. Such demand fluctuations could positively or negatively impact Genomics Companies.

**Currency Risk:** The Fund may invest in securities denominated in foreign currencies other than in the Base Currency of the Fund. Because the Fund’s NAV is determined in U.S. dollars, the Fund’s NAV could decline if currencies of the underlying securities depreciate against the U.S. dollar or if there are delays or limits on repatriation of such currencies. Currency exchange rates can be very volatile and can change quickly and unpredictably. As a result, the Fund’s NAV may change quickly and without warning, which could have a significant negative impact on the Fund.

**Risks Related to Investing in the Biotechnology Industry:** Biotechnology companies face intense competition and the potential for rapid product obsolescence. Biotechnology companies may be adversely affected by the loss or impairment of intellectual property rights or changes in government regulations. Demand for Biotechnology products and services, generally speaking and specific to sub-segments, may fluctuate due to unexpected events, including but not limited to global health crises like pandemics which could strain health care systems and alter health care needs. Such demand fluctuations could positively or negatively impact Biotechnology companies.

**Risks Related to Investing in the Health Care Sector:** The health care sector may be affected by government regulations and government health care programs, increases or decreases in the cost of medical products and services, an increased emphasis on outpatient services, and product liability claims,

among other factors. Many health care companies are heavily dependent on patent protection, and the expiration of a company's patent may adversely affect that company's profitability. Health care companies are subject to competitive forces that may result in price discounting and may be thinly capitalised and susceptible to product obsolescence. Companies in the Health Care Sector may also be affected by unforeseen circumstances including but not limited to the spread of infectious disease which could impact drug development priorities and pipelines, supply and demand dynamics for health care equipment, as well as the ability to receive care in health care service facilities.

**Risk of Investing in the United States:** A decrease in imports or exports, changes in trade regulations and/or an economic recession in the U.S. may have a material adverse effect on the U.S. economy and the securities listed on U.S. exchanges. Proposed and adopted policy and legislative changes in the U.S. are changing many aspects of financial and other regulation and may have a significant effect on the U.S. markets generally, as well as on the value of certain securities. In addition, a continued rise in the U.S. public debt level or the imposition of U.S. austerity measures may adversely affect U.S. economic growth and the securities to which a Fund has exposure. The U.S. has developed increasingly strained relations with a number of foreign countries. If these relations continue to worsen, it could adversely affect U.S. issuers as well as non-U.S. issuers that rely on the U.S. for trade. The U.S. has also experienced increased internal unrest and discord. If this trend were to continue, it may have an adverse impact on the U.S. economy and the issuers in which a Fund invests.

## **RISK MANAGEMENT**

---

The Fund's global exposure, being the incremental exposure and leverage generated by the Fund through its use of FDI, shall be calculated on at least a daily basis using the commitment approach and, in accordance with the requirements of the Central Bank, may at no time exceed 100% of the Fund's Net Asset Value. As noted in the "Investment Policy" section above, the Fund's use of FDI is an ancillary element of the investment policy in that it is an alternative means of gaining exposure to the Index, or one or more of the constituents of the Index, in circumstances where direct investment in the constituents of the Index is not possible, practicable or desirable. Regardless of whether exposure to the underlying constituents is obtained by direct investment in the constituents, or by gaining exposure to the constituents through the use of FDI, the same notional value shall be committed to the investment by the Fund. Accordingly, it is not expected that the Fund will be leveraged.

## **THE INDEX**

---

### **General Description**

The Index is designed to provide exposure to Genomics & Biotechnology Companies as defined by the Index Provider. In order to be eligible for inclusion in the Index, a company is considered by Solactive AG to be a company to be included if it generates revenues from relevant activities:

1. Pure-Play which derives at least 50% of revenues from Genomics Activities.
2. Pre-Revenue which has primary business operations in Genomics Activities but does not currently generate revenues.
3. Diversified which derives revenues from Genomics Activities but less than 50%.

Genomics business operations include but are not limited to the following: (i) Gene Editing (ii) Genomic Sequencing (iii) Development and Testing of Genetic Medicine/Therapies, and/or (iv) Computational

Genomics and Genetic Diagnostics. The remaining companies are ranked by their Index Score as defined above.

In constructing the Index, Solactive AG first establishes the eligible universe by utilising FactSet sector classifications: only companies classified by FactSet as healthcare companies are eligible for the Index. Solactive AG then applies a proprietary natural language processing algorithm to the eligible universe, which seeks to identify and rank companies with direct exposure to the genomics industry based on filings, disclosures and other public information (e.g. regulatory filings, earnings transcripts, etc).

The eligible universe of the Index includes exchange-listed companies that meet minimum market capitalisation and liquidity criteria, as defined by Solactive AG. As of 19 April 2024, companies must have a minimum market capitalisation of \$200 million and a minimum average daily turnover for the last 6 months greater than or equal to \$2 million in order to be eligible for inclusion in the Index. As of 13 December 2024, companies listed in the following countries were eligible for inclusion in the Index: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Singapore, Spain, Sweden, Switzerland, the United Kingdom, and the United States.

The Index is weighted according to a modified capitalisation weighting methodology whereby each component is subject to a maximum weight of 4% and the aggregate weight of diversified companies cannot exceed 10% of the index weight, and the maximum weight of a diversified company is 2%. The excess weight that results from implementing these constraints is redistributed proportionally such that none of the above constraints are breached. The Index is reconstituted and re-weighted semi-annually. The Index may include large-, mid- or small-capitalisation companies, and components primarily include healthcare companies. As of 31 December 2024, the Index had 40 constituents.

### **Index Rebalancing**

The Index shall be rebalanced on a semi-annual basis on the second Friday in May and the second Friday in November. It is possible that additional companies not presently represented in the Index will be added and that one or more companies presently represented will be removed at the time of the semi-annual rebalance dates.

Investors should note that the respective weights of each of the constituents of the Index are expected to fluctuate in-between the periodic rebalance dates of the Index. Please see the Prospectus section entitled *“Circumstances where the weighting of an Index constituent exceeds the applicable concentration limits prescribed by the UCITS Regulations”* for details of the procedure to be adopted when the weighting of any constituent of the Index exceeds the permitted investment restrictions.

The information set out above is a summary of the principal features of the Index and does not purport to be an exhaustive description. Further information can be found in *“Index Guideline Solactive Genomics v2 Index”* (the **“Index Methodology”**) which is available, along with the constituents and weights of the Index at: <https://www.solactive.com/indices/?index=DE000SL0C6K7>.

### **Index Provider**

The Benchmark Administrator is Solactive AG and the Index is calculated by Solactive AG.

The Index is sponsored by Solactive AG as the Index Provider, which is an organisation that is independent of the Fund and Global X Management Company LLC, the Investment Manager for the Fund. The Index Provider determines the relative weightings of the securities in the Index and publishes information regarding the market value of the Index.

## **TAXATION**

---

### **German Investment Tax Act**

The ICAV seeks to maintain “equity fund” status for the Fund pursuant to Section 2 para. 6 and 7 of the German Investment Tax Act 2018.

Investors should consult their own professional advisers as to the implications of the Fund maintaining “equity fund” status pursuant to the German Investment Tax Act 2018.

As at the date of this Fund Supplement, at least 51% of the Fund’s assets will be continuously invested in equity assets as defined in Section 2. para. 8 of the German Investment Tax Act 2018.

## **DISCLAIMERS**

---

The ICAV is required to provide details of the Index Provider’s website to enable investors to obtain further details of the Index (including its constituents). Neither the ICAV nor the Investment Manager has any responsibility for the contents of such website and are not involved in any way in sponsoring, endorsing or otherwise involved in the establishment, maintenance or contents of the website.

Solactive AG is a leading company in the structuring and indexing business for institutional clients. Solactive AG runs the Solactive index platform. Solactive AG indices are used by issuers worldwide as underlying indices for financial products. Solactive AG does not sponsor, endorse or promote any Fund and is not in any way connected to it and does not accept any liability in relation to their issue, operation and trading.

## **LISTINGS**

---

### **Euronext Dublin and the London Stock Exchange Listings**

Application has been made to Euronext Dublin/The London Stock Exchange for the Shares of the Fund issued and available for issue to be admitted to the Official List and to trading on the Regulated Market of Euronext Dublin/The London Stock Exchange. Admission to listing is expected to become effective on or about the date of this Fund Supplement or later date as the Directors may determine subject to the prior notification to Euronext Dublin/The London Stock Exchange. This document, together with the Prospectus shall constitute listing particulars for the purpose of listing the Shares on Euronext Dublin/The London Stock Exchange and includes all information required to be disclosed by the code of listing requirements and procedures of Euronext Dublin/The London Stock Exchange.

As of the date of this document the Fund does not have any loan capital (including term loans) outstanding or created but unissued, and no outstanding mortgages, charges, debentures or other borrowings under

acceptances or acceptance credits, hire purchase or finance lease commitments, guarantees or other contingent liabilities.

At the date of this document, other than as disclosed below, no Director or any persons closely associated with any Director, has any interest, beneficial or non-beneficial, in the share capital of the ICAV, together with any options in respect of such shares, or any material interest in the ICAV or in any agreement or arrangement with the ICAV except that one or more of the Directors may hold Subscriber Shares as a nominee of the Marketing Agent. The Directors shall endeavour to ensure that any conflict of interest is resolved fairly.